Acuvail FDA Approval History
FDA Approved: Yes (First approved July 22, 2009)
Brand name: Acuvail
Generic name: ketorolac tromethamine
Dosage form: Ophthalmic Solution
Company: Allergan, Inc.
Treatment for: Postoperative Ocular Inflammation
Acuvail (ketorolac tromethamine) is a preservative-free formulation of ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain and inflammation following cataract surgery.
Development timeline for Acuvail
| Date | Article |
|---|---|
| Jul 23, 2009 | Approval Allergan Receives FDA Approval for Acuvail Ophthalmic Solution for the Treatment of Pain and Inflammation Following Cataract Surgery |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
